PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug pill combo tested for Tough-to-Treat ovarian cancer
Disease control OngoingThis study is testing a combination of two oral medications, olaparib and cediranib, for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned after previous treatment. The goal is to see if taking these two drugs together can slow or stop cancer growth b…
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC